Teva inks accord on IP in the field of anti-CGRP-based therapy

9 January 2018

Israel-based Teva Pharmaceutical Industries (NYSE:TEVA) says its German subsidiary has signed a global license agreement with Alder BioPharmaceuticals (Nasdaq: ALDR), with the news sending Alder’s share up 17.37% to $15.20 by close of trading on Monday.

The agreement validates Teva's intellectual property (IP) and resolves Alder's opposition to Teva's European Patent No 1957106 B1, with respect to anti-calcitonin gene-related peptide (CGRP) antibodies and methods for their use. It also provides Alder with clarity for its ongoing plans in the field.

Under the terms of the agreement, Alder has received a non-exclusive license to Teva's anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize migraine drug candidate eptinezumab – a rival to Teva’s anti-CGRP investigational drug fremanezumab - in the USA and worldwide, excluding Japan and Korea. In exchange, Alder has agreed to:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK